NCT06993688 Revealing Information Genuinely & Honestly Across Time - Communication Preferences Visit
| NCT ID | NCT06993688 |
| Status | Recruiting |
| Phase | — |
| Sponsor | St. Jude Children's Research Hospital |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 85 participants |
| Start Date | 2025-06-16 |
| Primary Completion | 2027-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 85 participants in total. It began in 2025-06-16 with a primary completion date of 2027-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research study is to obtain insights and feedback from patients and parents about a new approach to support conversations about how cancer may affect one's future life and quality of life (i.e., prognostic communication). This study involves creating a personalized approach to discussing prognosis. Primary Objectives * To evaluate the feasibility of implementing the RIGHTimeCPV intervention among pediatric oncology patients, caregivers, and clinicians (referred to herein as "shareholders"). * To assess the acceptability of the intervention across the shareholder groups. Secondary Objectives * To explore the potential impact of the RIGHTimeCPV intervention on communication quality, concordance in prognostic understanding, and therapeutic alliance between patients/families and multidisciplinary clinicians. * To explore whether the practice of eliciting, sharing, and honoring individualized communication preferences is sustained by clinicians after participation in the RIGHTimeCPV intervention.
Eligibility Criteria
Inclusion Criteria: Patients * Aged 12-25 years diagnosed with poor prognosis cancer (high risk or otherwise difficult to treat cancers), as defined by a pediatric oncologist estimating odds of overall survival as 50% or less * Anticipated by a pediatric oncologist to have one or more disease re-evaluation timepoints over the next six months * Not anticipated by a pediatric oncologist to approach end of life in the next three months Inclusion Criteria: Parents/Caregivers * Aged 18 years or older and/or legally emancipated * Parent or other self-identified caregiver of a patient of any age with poor prognosis cancer (as defined above) Inclusion Criteria: Oncologists * Pediatric oncologists who treat eligible patients/caregivers at the study site, St. Jude Children's Research Hospital (SJCRH) or its included affiliates: * Peoria, IL: The Jim and Trudy Maloof St. Jude Midwest Affiliate Clinic * Charlotte, NC: Novant Health Hemby Children's Hospital * Shreveport, LA: Ochsner LSU Health-Feist-Weiller Cancer Center Inclusion Criteria: Communication Preferences Companions (CPCs) * Multidisciplinary clinicians from a participant's psychosocial or nursing care team, identified by that participant to serve as their 'communication preferences companion' (CPC) during the pilot * Provides clinical care to pediatric cancer patients under the auspices of psychology, social work, spiritual care, child life, cultural navigation, quality of life/palliative care, or nursing Exclusion Criteria: * Does not meet the stated inclusion criteria
Contact & Investigator
Erica C. Kaye, MD, MPH
PRINCIPAL INVESTIGATOR
St. Jude Children's Research Hospital
Frequently Asked Questions
Who can join the NCT06993688 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06993688 currently recruiting?
Yes, NCT06993688 is actively recruiting participants. Contact the research team at referralinfo@stjude.org for enrollment information.
Where is the NCT06993688 trial being conducted?
This trial is being conducted at Memphis, United States.
Who is sponsoring the NCT06993688 clinical trial?
NCT06993688 is sponsored by St. Jude Children's Research Hospital. The principal investigator is Erica C. Kaye, MD, MPH at St. Jude Children's Research Hospital. The trial plans to enroll 85 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.